Relation between bone marrow angiogenesis and serum levels of angiogenin in patients with myelodysplastic syndromes

被引：26

作者：

Alexandrakis, MG

Passam, FH

Pappa, CA

Sfiridaki, K

Tsirakis, G

Damilakis, J

Stathopoulos, EN

Kyriakou, DS

机构：

[1] Univ Hosp Heraklion, Sch Med, Dept Haematol, Iraklion, Crete, Greece

[2] Sotiria Hosp, Sch Med, Dept Internal Med 3, Haematol Unit, Athens, Greece

[3] Venizelion Gen Hosp, Dept Haematol, Iraklion, Crete, Greece

[4] Univ Hosp Heraklion, Sch Med, Dept Phys Med, Iraklion, Crete, Greece

[5] Univ Hosp Heraklion, Sch Med, Dept Pathol, Iraklion, Crete, Greece

[6] Univ Hosp Larisa, Sch Med, Dept Haematol, Larisa, Greece

来源：

LEUKEMIA RESEARCH | 2005年 / 29卷 / 01期

关键词：

myelodysplastic syndromes; angiogenesis; angiogenin; microvessel density;

D O I：

10.1016/j.leukres.2004.05.002

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

Angiogenesis is implicated in the progression of myelodysplastic syndromes (MDS). Bone marrow microvascular density (MVD), serum angiogenin (ANG) and interleukin 6 (IL-6) were measured in 67 patients with untreated MDS. MVD, ANG and IL-6 were significantly higher in the patient group as a whole when compared to controls (P < 0.01). MVD and ANG were significantly higher in subtypes with a high-risk for leukemic transformation (RAEB, RAEB-t and CMML) than in low-risk subtypes (RA and RARS) (P < 0.01). In the MDS group, a positive correlation was found between ANG and IL-6 (P < 0.001) and also between MVD and IL-6 (P < 0.05). Using multivariate analysis, only IL-6 displayed independent prognostic value and was inversely related to MDS survival. (C) 2004 Elsevier Ltd. All rights reserved.

引用

页码：41 / 46

页数：6

共 38 条

[1] Angiogenesis in acute and chronic leukemias and myelodysplastic syndromes [J].

Aguayo, A ;

Kantarjian, H ;

Manshouri, T ;

Gidel, C ;

Estey, E ;

Thomas, D ;

Koller, C ;

Estrov, Z ;

O'Brien, S ;

Keating, M ;

Freireich, E ;

Albitar, M .

BLOOD, 2000, 96 (06) :2240-2245

[2] Angiogenesis in acute myeloid leukemia and myelodysplastic syndrome [J].

Albitar, M .

ACTA HAEMATOLOGICA, 2001, 106 (04) :170-176

[3]

Alexandrakis M, 1998, HAEMATOLOGIA, V29, P13

[4] THE ACUTE-PHASE RESPONSE [J].

BAUMANN, H ;

GAULDIE, J .

IMMUNOLOGY TODAY, 1994, 15 (02) :74-80

[5]

BENNETT JM, 1982, BRIT J HAEMATOL, V51, P189, DOI 10.1111/j.1365-2141.1982.tb08475.x

[6] Blood levels of angiogenin and vascular endothelial growth factor are elevated in myelodysplastic syndromes and in acute myeloid leukemia [J].

Brunner, B ;

Gunsilius, E ;

Schumacher, P ;

Zwierzina, H ;

Gastl, G ;

Stauder, R .

JOURNAL OF HEMATOTHERAPY & STEM CELL RESEARCH, 2002, 11 (01) :119-125

[7]

CHOOPRA V, 1997, J CANCER RES CLIN, V123, P167

[8] Angiogenesis and metastasis [J].

Ellis, LM ;

Fidler, IJ .

EUROPEAN JOURNAL OF CANCER, 1996, 32A (14) :2451-2460

[9] ANGIOGENESIS IN CANCER, VASCULAR, RHEUMATOID AND OTHER DISEASE [J].

FOLKMAN, J .

NATURE MEDICINE, 1995, 1 (01) :27-31

[10] International scoring system for evaluating prognosis in myelodysplastic syndromes [J].

Greenberg, P ;

Cox, C ;

LeBeau, MM ;

Fenaux, P ;

Morel, P ;

Sanz, G ;

Sanz, M ;

Vallespi, T ;

Hamblin, T ;

Oscier, D ;

Ohyashiki, K ;

Toyama, K ;

Aul, C ;

Mufti, G ;

Bennett, J .

BLOOD, 1997, 89 (06) :2079-2088

← 1 2 3 4 →